TY - JOUR
T1 - A worldwide map of Plasmodium falciparum K13-propeller polymorphisms
AU - Ménard, Didier
AU - Khim, Nimol
AU - Beghain, Johann
AU - Adegnika, Ayola A.
AU - Shafiul-Alam, Mohammad
AU - Amodu, Olukemi
AU - Rahim-Awab, Ghulam
AU - Barnadas, Céline
AU - Berry, Antoine
AU - Boum, Yap
AU - Bustos, Maria D.
AU - Cao, Jun
AU - Chen, Jun Hu
AU - Collet, Louis
AU - Cui, Liwang
AU - Thakur, Garib Das
AU - Dieye, Alioune
AU - Djallé, Djibrine
AU - Dorkenoo, Monique A.
AU - Eboumbou-Moukoko, Carole E.
AU - Espino, Fe Esperanza Caridad J.
AU - Fandeur, Thierry
AU - Ferreira-Da-Cruz, Maria Fatima
AU - Fola, Abebe A.
AU - Fuehrer, Hans Peter
AU - Hassan, Abdillahi M.
AU - Herrera, Socrates
AU - Hongvanthong, Bouasy
AU - Houzé, Sandrine
AU - Ibrahim, Maman L.
AU - Jahirul-Karim, Mohammad
AU - Jiang, Lubin
AU - Kano, Shigeyuki
AU - Ali-Khan, Wasif
AU - Khanthavong, Maniphone
AU - Kremsner, Peter G.
AU - Lacerda, Marcus
AU - Leang, Rithea
AU - Leelawong, Mindy
AU - Li, Mei
AU - Lin, Khin
AU - Mazarati, Jean Baptiste
AU - Ménard, Sandie
AU - Morlais, Isabelle
AU - Muhindo-Mavoko, Hypolite
AU - Musset, Lise
AU - Na-Bangchang, Kesara
AU - Nambozi, Michael
AU - Niaré, Karamoko
AU - Noedl, Harald
AU - Ouédraogo, Jean Bosco
AU - Pillai, Dylan R.
AU - Pradines, Bruno
AU - Quang-Phuc, Bui
AU - Ramharter, Michael
AU - Randrianarivelojosia, Milijaona
AU - Sattabongkot, Jetsumon
AU - Sheikh-Omar, Abdiqani
AU - Silué, Kigbafori D.
AU - Sirima, Sodiomon B.
AU - Sutherland, Colin
AU - Syafruddin, Din
AU - Tahar, Rachida
AU - Tang, Lin Hua
AU - Touré, Offianan A.
AU - Tshibangu-Wa-Tshibangu, Patrick
AU - Vigan-Womas, Inès
AU - Warsame, Marian
AU - Wini, Lyndes
AU - Zakeri, Sedigheh
AU - Kim, Saorin
AU - Eam, Rotha
AU - Berne, Laura
AU - Khean, Chanra
AU - Chy, Sophy
AU - Ken, Malen
AU - Loch, Kaknika
AU - Canier, Lydie
AU - Duru, Valentine
AU - Legrand, Eric
AU - Barale, Jean Christophe
AU - Stokes, Barbara
AU - Straimer, Judith
AU - Witkowski, Benoit
AU - Fidock, David A.
AU - Rogier, Christophe
AU - Ringwald, Pascal
AU - Ariey, Frederic
AU - Mercereau-Puijalon, Odile
N1 - Funding Information:
Supported by the Institut Pasteur Paris, Institut Pasteur International Division, Institut Pasteur Cambodia, and the World Health Organization; by a grant (ANR-10-LABX-62-IBEID) from the French Government Investissement d'Avenir program, Laboratoire d'Excellence "Integrative Biology of Emerging Infectious Diseases"; a grant from Natixis Banques; a grant (R01 AI109023, to Dr. Fidock) from the National Institutes of Health; grants from the Fiocruz Fundação Oswaldo Cruz, Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro, Fundação de Amparo à Pesquisa do Estado do Amazonas, the Brazilian National Council for Scientific and Technological Development, the Agence Nationale de la Recherche (13-BSV3-0018-01 and 11-BSV7-009-01), the Austrian Federal Ministry of Science, Research, and Economy, the Calgary Laboratory Services, the Centre International de Recherches Médicales de Franceville, the European and Developing Countries Clinical Trials Partnership (CT-2004-31070-001), the Drugs for Neglected Diseases Initiative, the Else Kroener Fresenius Stiftung, the Holger Poehlmann Stiftung, the European Community African-European Research Initiative "IDEA" (HEALTH-F3-2009-241642), the Fonds Wetenschappelijk Onderzoek, the Vlaamse Interuniversitaire Raad-Universitaire Ontwikkelingssamenwerking, the Belgian Technical Cooperation in Democratic Republic of Congo, the European Community Seventh Framework Program (FP7/2007-2013, 242095, and 223601), the European Commission (REGPOT-CT-2011-285837-STRONGER), the Ministère de la Santé Publique du Niger (Laboratoire National de Référence Résistance aux Antipaludiques), the Foundation of National Science and Technology Major Program (2012ZX10004-220), the French Ministry of Health (Institut National de Veille Sanitaire), the Global Fund to Fight AIDS, Tuberculosis and Malaria, the 5% Initiative program (French Ministry of Foreign Affairs, France Expertise Internationale, 12INI109), the Institut Pasteur de Madagascar, the Government of the Philippines, The Institut de Recherche pour le Développement, the Foundation des Treilles, the Délégation Générale pour l'Armement (PDH-2-NRBC-4-B1-402), the Institut Pasteur de Bangui, the International Society for Health Research and Training, the Malaria Research Initiative Bandarban, Vienna, International Centre for Diarrhoeal Disease Research, Bangladesh, the Médecins sans Frontières (Centre Opérationnel Paris, France), Medicines for Malaria Venture, the National Research Council of Thailand, the Thammasat University, the National Natural Science Foundation of China (81271870, 81361120405, and 81271863), the Natural Science Foundation of Jiangsu Province (BK20130114 and BK20150001), the Jiangsu Science and Technology Department (BM2015024), the National Institutes of Health (R01 AI11646601, AI109023, and ICEMR U19AI089702, U19AI089672), the Pasteur Institute of Iran, the Malaria Division of the Iranian Center for Diseases Management and Control, Public Health England (Malaria Reference Service Contract), the Government of Rwanda, the U.S. Department of Defense Armed Forces Health Surveillance Center, Global Emerging Infections Surveillance and Response System (P0463-14-N6), the Fogarty International Center of the National Institutes of Health training (D43 TW007393), the Mahidol-Oxford Research Unit, the Government of Japan (Science and Technology Agency, Agency for Medical Research and Development, Japan International Cooperation Agency, and Science and Technology Research Partnership for Sustainable Development), and the President's Malaria Initiative of the U.S. Agency for International Development.
Publisher Copyright:
Copyright © 2016 Massachusetts Medical Society.
PY - 2016/6/23
Y1 - 2016/6/23
N2 - BACKGROUND Recent gains in reducing the global burden of malaria are threatened by the emergence of Plasmodium falciparum resistance to artemisinins. The discovery that mutations in portions of a P. falciparum gene encoding kelch (K13)-propeller domains are the major determinant of resistance has provided opportunities for monitoring such resistance on a global scale. METHODS We analyzed the K13-propeller sequence polymorphism in 14,037 samples collected in 59 countries in which malaria is endemic. Most of the samples (84.5%) were obtained from patients who were treated at sentinel sites used for nationwide surveillance of antimalarial resistance. We evaluated the emergence and dissemination of mutations by haplotyping neighboring loci. RESULTS We identified 108 nonsynonymous K13 mutations, which showed marked geographic disparity in their frequency and distribution. In Asia, 36.5% of the K13 mutations were distributed within two areas - one in Cambodia, Vietnam, and Laos and the other in western Thailand, Myanmar, and China - with no overlap. In Africa, we observed a broad array of rare nonsynonymous mutations that were not associated with delayed parasite clearance. The gene-edited Dd2 transgenic line with the A578S mutation, which expresses the most frequently observed African allele, was found to be susceptible to artemisinin in vitro on a ring-stage survival assay. CONCLUSIONS No evidence of artemisinin resistance was found outside Southeast Asia and China, where resistance-associated K13 mutations were confined. The common African A578S allele was not associated with clinical or in vitro resistance to artemisinin, and many African mutations appear to be neutral. (Funded by Institut Pasteur Paris and others.
AB - BACKGROUND Recent gains in reducing the global burden of malaria are threatened by the emergence of Plasmodium falciparum resistance to artemisinins. The discovery that mutations in portions of a P. falciparum gene encoding kelch (K13)-propeller domains are the major determinant of resistance has provided opportunities for monitoring such resistance on a global scale. METHODS We analyzed the K13-propeller sequence polymorphism in 14,037 samples collected in 59 countries in which malaria is endemic. Most of the samples (84.5%) were obtained from patients who were treated at sentinel sites used for nationwide surveillance of antimalarial resistance. We evaluated the emergence and dissemination of mutations by haplotyping neighboring loci. RESULTS We identified 108 nonsynonymous K13 mutations, which showed marked geographic disparity in their frequency and distribution. In Asia, 36.5% of the K13 mutations were distributed within two areas - one in Cambodia, Vietnam, and Laos and the other in western Thailand, Myanmar, and China - with no overlap. In Africa, we observed a broad array of rare nonsynonymous mutations that were not associated with delayed parasite clearance. The gene-edited Dd2 transgenic line with the A578S mutation, which expresses the most frequently observed African allele, was found to be susceptible to artemisinin in vitro on a ring-stage survival assay. CONCLUSIONS No evidence of artemisinin resistance was found outside Southeast Asia and China, where resistance-associated K13 mutations were confined. The common African A578S allele was not associated with clinical or in vitro resistance to artemisinin, and many African mutations appear to be neutral. (Funded by Institut Pasteur Paris and others.
UR - http://www.scopus.com/inward/record.url?scp=84975522970&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84975522970&partnerID=8YFLogxK
U2 - 10.1056/NEJMoa1513137
DO - 10.1056/NEJMoa1513137
M3 - Article
C2 - 27332904
AN - SCOPUS:84975522970
SN - 0028-4793
VL - 374
SP - 2453
EP - 2464
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 25
ER -